Expansion of healthcare-related operations through the dispensing-pharmacy business
First written in FY2016. 11 of 24 entries say "Restated". Latest entry: FY2026-H1.
Alfresa Holdings moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2025: 1 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「In the prescription pharmacy and related businesses, the consolidated subsidiary アポクリート株式会社 (head office: Toshima, Tokyo) is pursuing the following initiatives under the theme of becoming a primary-care pharmacy needed by the community: enhancing patient-facing services and securing prescriptions, strengthening the acquisition of prescriptions from medical institutions other than neighboring clinics, expanding new pharmacy functions, and entering the nursing care business. These are priority measures under the 25-27 Medium-Term Management Plan.」
The prescription pharmacy business was reorganized from the 22-24 Medium-Term Management Plan's initiatives centered on home healthcare, digital transformation and disease prevention before onset into the priority measures of the 25-27 Medium-Term Management Plan, including patient services, prescription acquisition, expanded pharmacy functions and entry into the nursing care business. - FY2025-H1RestatedAnnual report
「In the healthcare-related business, アポクリート株式会社 (head office: Toshima-ku, Tokyo), a consolidated subsidiary operating the prescription pharmacy business, aims to be a “primary care pharmacy” serving every stage of the life journey, from prevention to terminal care, and is promoting the “growth of the business through home healthcare,” “business transformation through DX,” and “initiatives for presymptomatic disease prevention,” identified as priority measures under the “22-24 Medium-Term Management Plan.”」
The Group continues to promote home healthcare, digital transformation and disease prevention before onset, aiming to become a primary-care pharmacy serving every stage of the customer's life journey. - FY2024AdvancedAnnual report
「As part of its efforts to grow the business through home healthcare, in September 2023 the company acquired all shares of 有限会社会営, which operates prescription pharmacies including the “カイエー薬局グループ” in Saitama Prefecture, making it a wholly owned subsidiary. The company will continue working to establish a regional home healthcare-dominant platform.」
アポクリート acquired all shares of 有限会社会営, which operates prescription pharmacies, making it a wholly owned subsidiary and giving concrete shape to the regional expansion of its home healthcare business. - FY2023-Q2RestatedAnnual report
「In the healthcare-related business, we aim to be a “primary care pharmacy” serving every stage of the life journey, from prevention to terminal care, and are promoting the “growth of the business through home healthcare,” “business transformation through DX,” and “initiatives for presymptomatic disease prevention,” identified as priority measures under the “22-24 Medium-Term Management Plan.”」
In the prescription pharmacy business, the Group continues to promote initiatives in home healthcare, digital transformation and disease prevention before onset, aiming to become a primary-care pharmacy serving every stage of the customer's life journey. - FY2023-Q1ReframedAnnual report
「In the healthcare-related business, we aim to be a “primary care pharmacy” serving every stage of the life journey, from prevention to terminal care, and are promoting the “growth of the business through home healthcare,” “business transformation through DX,” and “initiatives for presymptomatic disease prevention,” identified as priority measures under the “22-24 Medium-Term Management Plan.”」
The prescription pharmacy business has moved beyond its previous focus on efficiency and integration, and has taken more concrete shape as a direction to promote home healthcare, digital transformation and disease prevention before onset, positioning pharmacies as primary-care pharmacies serving every stage of the customer's life journey. - FY2022-Q3RestatedAnnual report
「In April 2021, the consolidated subsidiary アポロメディカルホールディングス株式会社 (head office: Toshima, Tokyo), 株式会社日本アポック (head office: Kawagoe, Saitama), and the Company's wholly owned subsidiary 株式会社中日ファーマシー (head office: Naka, Nagoya) merged, with アポロメディカルホールディングス株式会社 as the surviving company, and changed their corporate name to アポクリート株式会社. Through the management integration of the 3 companies, the Group aims to strengthen and improve the efficiency of the prescription pharmacy business platform, further strengthen its compliance efforts, and create new value from the customer's perspective.」
The Group continues to describe the integration of the 3 prescription pharmacy companies, the change of corporate name to アポクリート, and its policy of strengthening the management platform, improving efficiency and enhancing compliance. - FY2022-Q1AdvancedAnnual report
「In April 2021, the consolidated subsidiary アポロメディカルホールディングス株式会社 (head office: Toshima, Tokyo), 株式会社日本アポック (head office: Kawagoe, Saitama), and the Company's wholly owned subsidiary 株式会社中日ファーマシー (head office: Naka, Nagoya) merged, with アポロメディカルホールディングス株式会社 as the surviving company, and changed their corporate name to アポクリート株式会社.」
The integration of the 3 prescription pharmacy companies was completed, and the surviving company changed its corporate name to アポクリート株式会社. - FY2021AdvancedAnnual report
「In January 2021, the consolidated subsidiary アポロメディカルホールディングス株式会社, 株式会社日本アポック and the Company's wholly owned subsidiary 株式会社中日ファーマシー entered into a merger agreement in which アポロメディカル would be the surviving company, and merged effective 1 April of the same year.」
The integration of the 3 prescription pharmacy companies progressed from signing the agreement to completing the merger effective 1 April 2021. - FY2021-Q3AdvancedAnnual report
「In January 2021, the consolidated subsidiary アポロメディカルホールディングス株式会社 (head office: Toshima, Tokyo), hereinafter アポロメディカル, 株式会社日本アポック (head office: Kawagoe, Saitama), and the Company's wholly owned subsidiary 株式会社中日ファーマシー (head office: Nagoya, Aichi) entered into a merger agreement in which アポロメディカル would be the surviving company (effective date: 1 April 2021).」
The 3 companies, アポロメディカル, 日本アポック and 中日ファーマシー, entered into a merger agreement, bringing the management integration of the prescription pharmacy business to the implementation stage. - FY2021-Q2AdvancedAnnual report
「In October 2020, the consolidated subsidiary アポロメディカル, 株式会社日本アポック (head office: Kawagoe, Saitama), and the Company's wholly owned subsidiary 株式会社中日ファーマシー (head office: Nagoya, Aichi), which operates the prescription pharmacy business, reached a basic agreement on a merger in which アポロメディカル would be the surviving company. Through the management integration of the 3 companies, the Group aims to optimize the allocation of management resources, further strengthen its compliance efforts, and create new value from the customer's perspective.」
Reached a basic agreement on the merger of アポロメディカル, 日本アポック and 中日ファーマシー, moving to the stage of optimizing management resources, strengthening compliance and creating customer-focused value. - FY2021-Q1AdvancedAnnual report
「In June 2020, for the purpose of strengthening the foundations and governance of the healthcare-related business (prescription pharmacy business), the company acquired additional shares in its consolidated subsidiary アポロメディカルホールディングス株式会社 (head office: Toshima-ku, Tokyo, hereinafter “アポロメディカル”), making it a wholly owned subsidiary.」
Acquired additional shares in アポロメディカル and made it a wholly owned subsidiary, strengthening the foundation and governance of the prescription pharmacy business. - FY2020-Q3RestatedAnnual report
「In the healthcare-related business, including dispensing pharmacies, we are pursuing the priorities set out in the 19-21 Medium-Term Management Plan to promote efficiency measures aimed at improving profitability and strengthen functions in response to changes in the operating environment: restructuring stores according to their functions, improving efficiency and sophistication to improve profitability, contributing to local communities through multifunctional operations, and strengthening coordination with each business segment.」
The company continues to pursue store restructuring, efficiency and sophistication, multifunctional operations and segment coordination in the healthcare-related business. - FY2020-Q2AdvancedAnnual report
「In the healthcare-related business, including dispensing pharmacies, we are pursuing the priorities set out in the 19-21 Medium-Term Management Plan to promote efficiency measures aimed at improving profitability and strengthen functions in response to changes in the operating environment: restructuring stores according to their functions, improving efficiency and sophistication to improve profitability, contributing to local communities through multifunctional operations, and strengthening coordination with each business segment.」
While continuing store restructuring, efficiency and sophistication, multifunctional operations and segment coordination, the company improved operating income from an operating loss of ¥15 million in the same period of the previous year to operating income of ¥190 million, owing to an increase in the number of stores and higher acquisition of dispensing-fee add-ons. - FY2020-Q1RestatedAnnual report
「In the healthcare-related business, including dispensing pharmacies, we are pursuing the priorities set out in the 19-21 Medium-Term Management Plan to promote efficiency measures aimed at improving profitability and strengthen functions in response to changes in the operating environment: restructuring stores according to their functions, improving efficiency and sophistication to improve profitability, contributing to local communities through multifunctional operations, and strengthening coordination with each business segment.」
In the healthcare-related business, including dispensing pharmacies, the company continues to pursue store restructuring, efficiency and sophistication, multifunctional operations and segment coordination as priorities under the new Medium-Term Management Plan. - FY2019ReframedAnnual report
「In the healthcare-related business, including the dispensing-pharmacy business, the company will promote efficiency measures aimed at improving profitability and strengthen functions to respond to changes in the operating environment.」
The company has given more concrete form to its priorities, shifting from the previous emphasis on expanding the healthcare-related domain through the dispensing-pharmacy business to regional contributions through store restructuring, more efficient and advanced functions, and multifunctional operations. - FY2019-Q3RestatedAnnual report
「In the healthcare-related business, we continue to pursue the “improvement of profitability” and “response to changes in business formats” identified as priority measures under the “16-18 Medium-Term Management Plan.”」
Improving earnings power and responding to changes in the business format remain key priorities in the healthcare-related business. Operating income fell 76.8% year on year owing to the impact of revisions to dispensing fees. - FY2019-Q2RestatedAnnual report
「In the healthcare-related business, we continue to pursue the “improvement of profitability” and “response to changes in business formats” identified as priority measures under the “16-18 Medium-Term Management Plan.”」
Improving earnings power and responding to changes in the business format remain key priorities in the healthcare-related business. - FY2019-Q1RestatedAnnual report
「In the healthcare-related business, we continue to pursue the “improvement of profitability” and “response to changes in business formats” identified as priority measures under the “16-18 Medium-Term Management Plan.”」
Improving earnings power and responding to changes in the business format remain key priorities in healthcare-related operations, including dispensing pharmacies. - FY2018-Q3RestatedAnnual report
「In October 2017, our consolidated subsidiary 株式会社日本アポック (head office: Kawagoe, Saitama) merged with our non-consolidated subsidiary 株式会社ユースケア. We will further strengthen the foundations of the prescription pharmacy business by making effective and efficient use of management resources.」
The company continues from the previous quarter to report the completion of the merger of 株式会社日本アポック and ユースケア and its policy of strengthening the foundation of the dispensing-pharmacy business. - FY2018-Q2AdvancedAnnual report
「In October 2017, consolidated subsidiary 株式会社日本アポック merged with non-consolidated subsidiary 株式会社ユースケア. The company will further strengthen the foundation of the dispensing-pharmacy business by using management resources effectively and efficiently.」
The merger of 株式会社日本アポック and ユースケア, which had been presented as a merger agreement in the previous quarter, was completed in October 2017. - FY2018-Q1AdvancedAnnual report
「In July 2017, our wholly owned subsidiary 株式会社日本アポック (head office: Kawagoe, Saitama) and 株式会社ユースケア (head office: Chiyoda-ku, Tokyo) entered into a merger agreement, with 1 October 2017 scheduled as the effective date. We will further strengthen the foundations of the prescription pharmacy business by making effective and efficient use of management resources.」
The merger agreement between 株式会社日本アポック and ユースケア has been signed, moving the dispensing-pharmacy business into a concrete restructuring phase aimed at strengthening its foundation. - FY2017-Q3RestatedAnnual report
「In our healthcare-related business, we are expanding our health and healthcare-related businesses toward realizing a “Healthcare Consortium.”」
The company continues to pursue expansion of the healthcare and medical-service domains in the healthcare-related business. It also states that revisions to dispensing fees had an impact. - FY2017-Q1RestatedAnnual report
「In our healthcare-related business, we are expanding our health and healthcare-related businesses toward realizing a “Healthcare Consortium.”」
The company continues to expand its healthcare and medical-service domains through healthcare-related operations, including dispensing pharmacies. - FY2016First statedAnnual report
「To realise a healthcare consortium, the company established a new healthcare-related business segment from the current consolidated fiscal year and consolidated アポロメディカルホールディングス株式会社, which operates dispensing pharmacies, and 株式会社日本アポック. In the healthcare-related business, the company will continue expanding its healthcare and medical-service domains.」
The company has made the dispensing-pharmacy business visible as an independent segment and continues to expand its healthcare and medical-service domains.